Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Overview

How likely is it that the drugs in Open-Angle Glaucoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Open-Angle Glaucoma Overview

Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to a buildup of aqueous humor (fluid) and an increase in intraocular pressure. Elevated pressure damages the optic nerve, which transmits visual information to the brain, causing gradual vision loss. Risk factors include age (more common in individuals over 40), family history of glaucoma, high IOP, certain medical conditions (such as diabetes and hypertension), and certain ethnicities (African Americans have a higher risk). Early-stage, open-angle glaucoma often presents without noticeable symptoms or vision changes. As the condition progresses, peripheral vision loss (usually unnoticed at first) gradually advances to tunnel vision and, if untreated, can lead to complete blindness.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Reasons to buy

  • Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
  • Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
  • Use PTSR and LOA information and event-driven changes for your investment decisions.

What our clients have to say

More Reports

View More Reports